Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Luye Files to Start China Trials of Class 1.1 Novel Analgesia Candidate

publication date: Jun 20, 2018

Luye Pharma of Yantai announced the CFDA accepted its IND filing for a China Class 1.1 novel analgesia candidate. LY03012 is an extended release oral treatment for chronic pain such as diabetic peripheral neuralgia, musculoskeletal pain and fibromyalgia. Although China is the first country to accept its IND, Luye intends to develop LY03012 in the US, Europe, Japan and other countries. The company expects to begin clinical trials soon. More details....

Stock Symbol: (HK: 2186)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.